ASH 2021 | Results of iStopMM: prevalence of smoldering myeloma in the general population
Sigrun Thorsteinsdottir, MD, National University Hospital of Iceland, Reykjavik, Iceland, describes the design and findings of iStopMM, a nationwide screening study investigating the prevalence of smoldering multiple myeloma in the general population (NCT03327597). Participants with abnormal screening results were randomized into three arms where they either did not receive additional care (Arm 1), or they received care according to current guidelines for patients with multiple myeloma precursor disease (Arm 2), or they were offered a more intensive care and follow-up strategy. The study identified 180 patients with smoldering multiple myeloma and the prevalence of this precursor condition in the general population was estimated to be 0.5%, with one-third of these patients having an intermediate to high risk of progression to multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
